Association between the Interleukin-6 Promoter Polymorphism-174G/C and Serum Lipoprotein(a) Concentrations in Humans
Association between the Interleukin-6 Promoter Polymorphism-174G/C and Serum Lipoprotein(a) Concentrations in Humans
复制标题
DOI：
10.1371/journal.pone.0024719
复制
发表时间：
2011-09-14
期刊：
影响因子：
3.7
通讯作者：
Gouni-Berthold, Ioanna
中科院分区：
文献类型：
--
作者：
Berthold, Heiner K.;Laudes, Matthias;Gouni-Berthold, Ioanna
背景：脂蛋白（a）[Lp（a）]是心血管疾病的独立危险因素。白细胞介素-6（IL-6）受体拮抗剂托珠单抗已被证明可降低血清Lp（a）浓度。我们研究了IL-6单核苷酸多态性-174 G/C是否与基线血清Lp（a）concentration.Methodology/Principal Findings相关：我们将来自Lipid Analytic科隆（LIANCO）队列的2321名受试者分为2组，Lp（a）显著升高的受试者定义为浓度>= 60 mg/dl（n = 510），Lp（a）显著升高的受试者定义为浓度>= 60 mg/dl（n = 510），Lp（a）显著升高的受试者定义为浓度>= 60 mg/dl（n = 510）。
Background: Lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease. The interleukin-6 (IL-6) receptor antagonist tocilizumab has been shown to lower serum Lp(a) concentrations. We investigated whether the IL-6 single nucleotide polymorphism -174G/C is associated with baseline serum Lp(a) concentrations.Methodology/Principal Findings: We divided 2321 subjects from the Lipid Analytic Cologne (LIANCO) cohort into 2 groups, the ones with substantially elevated Lp(a), defined as concentrations >= 60 mg/dl (n = 510), and the ones with Lp(a)